Relmada Therapeutics, Inc.


Latest Press Releases, Articles & Media Resources

Press Releases

April 13, 2017
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder

NEW YORK, April 13, 2017 /PRNewswire/ --┬áRelmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the company's novel N-methyl-D-aspartate (NMDA) receptor… Read More ┬╗

More Press Releases


View All Tweets